Overexpression of FRAT1 is associated with malignant phenotype and poor prognosis in human gliomas.
Glioma is the most common malignancy of the central nervous system. Approximately 40 percent of intracranial tumors are diagnosed as gliomas. Difficulties in treatment are associated closely with the malignant phenotype, which is characterized by excessive proliferation, relentless invasion, and angiogenesis. Although the comprehensive treatment level of brain glioma is continuously progressing, the outcome of this malignancy has not been improved drastically. Therefore, the identification of new biomarkers for diagnosis and therapy of this malignancy is of significant scientific and clinical value. FRAT1 is a positive regulator of the Wnt/β-catenin signaling pathway and is overexpressed in many human tumors. In the present study, we investigated the expression status of FRAT1 in 68 patients with human gliomas and its correlation with the pathologic grade, proliferation, invasion, angiogenesis, and prognostic significance. These findings suggest that FRAT1 may be an important factor in the tumorigenesis and progression of glioma and could be explored as a potential biomarker for pathological diagnosis, an indicator for prognosis, and a target for biological therapy of malignancy.
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China ; Department of Neurosurgery, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Geng
G
Guo
GCP Center, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300192, China ; Postdoctoral Programme, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Cheng-liang
CL
Zhong
Department of Neurosurgery, The Third Hospital of Mianyang, Mianyang, Sichuan 621000, China.
Yang
Y
Liu
Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
Xing-gang
XG
Mao
Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.
Zheng
Z
Zhang
Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Ji
J
Jin
Department of Neurosurgery, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Jing
J
Liu
Department of Neurology, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Liu
L
Yang
Department of Neurology, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Jin-ming
JM
Mao
Department of Neurosurgery, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Yu-hong
YH
Guo
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.
Yuan-li
YL
Zhao
D048868:Adaptor Proteins, Signal Transducing; D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D001932:Brain Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D016022:Case-Control Studies; D002648:Child; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005910:Glioma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism*; D015854:Up-Regulation
D048868:Adaptor Proteins, Signal Transducing; D014408:Biomarkers, Tumor; C491819:FRAT1 protein, human; D047908:Intracellular Signaling Peptides and Proteins; D011518:Proto-Oncogene Proteins